Fairvalue-Calculator Fairvalue-Calculator
EN DE

Bangkok Genomics Innovation Public Company (BKGI) Fair Value & Analysis

Healthcare · TH · Market cap 1.2B THB

Price2.06 THB
Fair Value1.51 THB
Upside-26.7%
Quality95/100
Evidence: High Range 1.13 THB – 1.89 THB

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Bangkok Genomics Innovation Public Company (BKGI) currently trades at 2.06 THB, while our model-based Fair Value estimate is 1.51 THB — implying the stock looks roughly 26.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand, preimplantation chromosomal abnormality and thalassemia carrier gene screening, infectious disease group analysis, and monkeypox virus analysis. It also provides other screening tests, such as cancer-related gene screening to predict the risk of inherited cancer, monitor treatment, select drugs that are appropriate for one's genetics, and provide treatment and disease prevention. In addition, the company offers genetic analysis using whole exome sequencing, a technology that can detect gene abnormalities that cause diseases; individual genetic decoding, which involves detailed genetic sequencing to analyze genetic information and identify aspects such as ethnicity or ancestry, optimal exercise profiles, metabolic capabilities, and the risk of genetic diseases; new…

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -54% Danaher Corporation (DHR) -54% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -53% Lonza Group (LZAGY) -77% Agilent Technologies, Inc (A) -52%

Frequently asked questions

Is Bangkok Genomics Innovation Public Company (BKGI) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 1.51 THB versus a price of 2.06 THB — about −27% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BKGI?
Our 21-model fair value for Bangkok Genomics Innovation Public Company is 1.51 THB (as of Jun 24, 2026), built from audited fundamentals. The current price is 2.06 THB.
What is the quality score of BKGI?
Bangkok Genomics Innovation Public Company has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.